Tela Bio, Inc. · NASDAQ:TELA
Tela Bio — Investor Presentation (November 2024)
20 slides from Tela Bio's investor presentation, Nov 7, 2024
Slide 1: Investor Presentation November 2024
INVESTOR PRESENTATION November 2024
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . All statements other than statements of historical facts contained in this document, including but not limited to statements regarding possi
Slide 3: Our Mission
We provide innovative soft - tissue reconstruction solutions that optimize clinical outcomes by prioritizing the Preservation and Restoration of the patient’s own anatomy. Our Mission 3
Slide 4: Redefining soft tissue preservation and restoration
1. Management estimate. $2.2B total includes $1.5B hernia & abdominal wall reconstruction, $0.7B plastic reconstructive surgery. Redefining soft tissue preservation and restoration with a differentiated category of tissue reinforcement materials and supportive products TELA Bio, Inc. ▫ Advanced rein
Slide 5: OviTex Reinforced Tissue Matrix
Sex 7 FINUR 2a eN a7 \f L B& st REINFORCED TISSUE MATRIX @TELABIO SCIENCE. VALUE. INNOVATION.
Slide 6: US Hernia Surgery Market: ~$1.5 Billion Annual Opportunity
Complex, Moderate Ventral / Abdominal Wall Reconstruction Simple Ventral Hernia Repair Inguinal Hernia Repair Hiatal Hernia Repair ~60,000 ~345,000 ~665,000 ~40,000 $360M $515M $600M $40M 1. Sources: Millennium Research Group Reports, IMS Health Data; iData Research MedSKU . 2. Management estimate.
Slide 7: OviTex hernia product portfolio
OviTex IHR 4 - layer and 3 - layer device No smooth sides Robot Compatible 2 : Yes OviTex IHR is designed specifically for use in inguinal hernia repair procedures. The design also incorporates an anatomical and rectangular shape to suit surgeon preference. 7 OviTex Core 4 - layer device No smooth s
Slide 8: Need for Alternative to Permanent Synthetic Mesh
8 Need for Alternative to Permanent Synthetic Mesh 1. Hernia and Abdominal Surgeries Survey (Oct 2020). A group of 71 surgeons were surveyed regarding use of mesh in various he rni a repair surgeries. 2. Figures derived from Company - sponsored online poll of approximately 1,100 potential patients f
Slide 9: Consistently Low Recurrence Rates
Source: Refer to “Clinical References” in this presentation. * Indicates one or more surgeons are paid consultants of TELA Bio, Inc. Consistently Low Recurrence Rates Backed by 8+ years of clinical experience and 43 published or presented works 9
Slide 10: Favorable Results of OviTex in Ventral Hernia Repair
*Overall complications including surgical site occurrences (SSOs) and surgical site infections (SSIs) a – OviTex patients were more complicated with a significantly higher mVHWG distribution and CDC wound classification compared to polypropylene patients. b – OviTex patients experienced significantl
Slide 11: Clinical study comparisons of hernia repair
* Kaplan - Meier survival estimate **No head - to - head clinical studies have been conducted. Due to differences in patient population, surgeons, surgical technique, and other variables, no direct comparisons of results can be made. For a comparative discussion of these studies, please see G. DeNot
Slide 12: Hernia Market Evolution
Hernia Market Evolution TELA Bio positioned to grow from a market shift towards resorbable and reinforced “natural repair” solutions as an alternative to traditional Permanent Synthetics or Biologics 12 Resorbable Synthetics and Reinforced Tissue Matrix strengths : Clinical Evidence Robot Compatibil
Slide 13: OviTex PRS Reinforced Tissue Matrix
OVITEX P} REINFORCED TISSUE MATRIX @TELABIO SCIENCE. VALUE. INNOVATION. B
Slide 14: Plastic and reconstructive surgery opportunity
Surgeons use products to reinforce soft tissue during various reconstructive surgeries 1 , including: ▫ Head and neck surgery ▫ Chest wall reconstruction ▫ Pelvic reconstruction ▫ Extremities reconstruction ▫ Breast reconstruction Cosmetic Plastic & Reconstructive Surgery $600M 2 $100M 2 Market domi
Slide 15: OviTex PRS features
An innovative reinforced tissue matrix designed to improve outcomes by facilitating fluid management and controlling degree and direction of stretch Product Features: ▫ Layers composed of biologic building block retain biologically significant macromolecules for tissue regeneration 1,2 ▫ Diamond emb
Slide 16: Leading-edge atraumatic hernia mesh fixation devices
Leading - edge atraumatic hernia mesh fixation devices Designed to minimize complications for patient safety and comfort 16
Slide 17: Atraumatic liquid fixation devices
Atraumatic liquid fixation device s ▫ Reduce the need for penetrating mechanical fixation for inguinal and femoral hernia repair ▫ Provide p rec ise , controlled adhesive application Addresses an unmet need in the market, less damage to tissue ▫ Designed to minimize the risk of mechanical tissue tra
Slide 18: Driving Revenue Growth
2021: 40 - 45 reps / 5 TB Ltd. 2022: 61 reps / 6 TB Ltd. 2023: 86 reps / 9 TB Ltd. 3Q24: 69 reps + 7 asst. reps / 10 TB Ltd. Rep Productivity Sales Force Size Product Portfolio GPO Access Clinical Experience $ ales >1,600 hospitals ~4,400 hospitals R&D and BD Third national GPO More to come 18 ▫ BRA
Slide 19: Delivering Revenue Growth and Margin Improvement
Q3 2024 Performance ▫ R ecord quarterly revenue of $19.0 M, growing 26 % over corresponding period of 2023 ▫ Cash and Cash Equivalents at September 30 , 2024: $17.3M ▫ Gross Margin: 68% ▫ The Company implemented cost - cutting measures in Q3, which are expected to result in reduced operating expense
Slide 20: Clinical References
20 Clinical References 1. Ankney , C.; Banaschak , C.; Sowers, B.; Szotek, P. Minimizing Retained Foreign Body in Hernia Repair Using a Novel Technique: Reinforced Biologic A ugm ented Repair ( ReBAR ). J Clin Medical Res 2021, doi:10.37191/mapsci - 2582 - 4333 - 3(4) - 073. 2. Sivaraj , D.; Henn, D